Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010

Phase 3

Completed

Conditions: Gout

Interventions: Drug: Febuxostat
Drug: Allopurinol

First Posted Date: 2005-09-15

Last Posted Date: 2010-07-27

Lead Sponsor: Takeda

Target Recruit Count: 1086

Registration Number: NCT00175019

Magnetic Resonance Imaging in Subjects With Gouty Tophi

Completed

Conditions: Hyperuricemia
Gout

Interventions: Procedure: MRI

First Posted Date: 2005-09-15

Last Posted Date: 2010-07-27

Lead Sponsor: Takeda

Target Recruit Count: 32

Registration Number: NCT00174954

A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin

Phase 3

Completed

Conditions: Osteoarthritis
Peptic Ulcer

Interventions: Drug: Lansoprazole and naproxen and aspirin
Drug: Celecoxib and aspirin

First Posted Date: 2005-09-15

Last Posted Date: 2010-07-22

Lead Sponsor: Takeda

Target Recruit Count: 1045

Registration Number: NCT00175032

Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis

Phase 2

Completed

Conditions: Esophagitis
Reflux

Interventions: Drug: Lansoprazole

First Posted Date: 2005-09-15

Last Posted Date: 2010-07-21

Lead Sponsor: Takeda

Target Recruit Count: 68

Registration Number: NCT00175045

Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout

Phase 2

Completed

Conditions: Gout

Interventions: Drug: Placebo
Drug: Febuxostat

First Posted Date: 2005-09-15

Last Posted Date: 2011-07-29

Lead Sponsor: Takeda

Target Recruit Count: 153

Registration Number: NCT00174967

Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Pioglitazone
Drug: Placebo

First Posted Date: 2005-09-15

Last Posted Date: 2012-02-28

Lead Sponsor: Takeda

Target Recruit Count: 4373

Registration Number: NCT00174993

Long-Term Safety of Febuxostat in Subjects With Gout.

Phase 2

Completed

Conditions: Gout

Interventions: Drug: Febuxostat

First Posted Date: 2005-09-15

Last Posted Date: 2011-01-27

Lead Sponsor: Takeda

Target Recruit Count: 116

Registration Number: NCT00174941

A Study to Evaluate the Effect of Lansoprazole on Hospitalized Neonates With Gastroesophageal Reflux Disease

Phase 1

Completed

Conditions: Gastroesophageal Reflux Disease

Interventions: Drug: Lansoprazole

First Posted Date: 2005-09-15

Last Posted Date: 2010-07-22

Lead Sponsor: Takeda

Target Recruit Count: 24

Registration Number: NCT00174928

Validation Study of Physical Measurement of Tophi

Completed

Conditions: Gout

Interventions: Other: Measurement of Tophi to validate procedure

First Posted Date: 2005-09-15

Last Posted Date: 2010-07-27

Lead Sponsor: Takeda

Target Recruit Count: 13

Registration Number: NCT00175006

Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-339)

Phase 3

Completed

Conditions: Gastroesophageal Reflux

First Posted Date: 2005-09-14

Last Posted Date: 2012-05-07

Lead Sponsor: Takeda

Target Recruit Count: 1200

Registration Number: NCT00163306

Locations: 🇵🇱
Altana Pharma/Nycomed, Tychy, Poland

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy